anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Air-conduction (AC) and bone-conduction (BC) thresholds were measured to evaluate standard reference thresholds and recommend revisions to audiometer standards. AC and BC thresholds were measured from listeners with normal hearing (NH) and sensorineural hearing loss (SNHL) at three sites. NH participants (n = 53) were selected based on age (18-25 years old), normal AC thresholds, tympanometry, otoscopy, and absence of otologic disease. SNHL participants (n = 49) were selected based on AC thresholds, tympanometry, otoscopy, and absence of otologic disease. AC thresholds obtained from NH listeners averaged 3.7 dB hearing level (HL). Air-bone gaps (ABGs) occurred in NH and SNHL listeners above 2000 Hz and in SNHL listeners at 250 Hz. Corrections to standard reference equivalent threshold sound pressure levels are recommended. ABGs in listeners without conductive pathology result from incorrect reference threshold levels for frequencies above 2000 Hz. False ABGs increase with hearing-loss magnitude, probably the result of the effects of ambient and internal noise for low-level BC stimuli. False ABGs place patients at risk for unnecessary medical and surgical intervention. Reference threshold levels should achieve two objectives: (1) AC thresholds from young NH listeners should average 0 dB HL; and (2) ABGs from listeners with normal middle-ear function should average 0 dB.
Hamstrings injuries are common among footballers with a higher prevalence rate in male footballers. Despite the relatively high incidence of hamstring injuries in sports, no clear prevention methods have been identified. Most hamstring muscle injuries occur during an eccentric phase of any activity. Eccentric hamstring training has been used for injury prevention in recent years. The two distinguishing characteristics of eccentric muscle contractions have been well understood: 1) great force output; and 2) low energy cost to produce the force. Due to these distinguishing characteristics, eccentric exercise is widely used in injury prevention programs.

The aim of this study is to determine the effectiveness of eccentric training as compared to conventional training in hamstring muscle injury prevention and strengthing in football players.
Two-year carcinogenicity studies in rodents have not been conducted with metreleptin. No proliferative or preneoplastic lesions were observed in mice or dogs following treatment up to six months. However, leptin is reported in the literature to promote cell proliferation in vitro and tumor progression in some mouse models of cancer.

Metreleptin was not mutagenic in the Ames bacterial mutagenicity assay or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells and human peripheral blood lymphocytes. Metreleptin was not mutagenic or clastogenic in an in vivo mouse micronucleus assay.

In a fertility study in mice, metreleptin had no adverse effects on mating, fertility, or early embryonic development at doses ranging between 7 and 15 times the maximum recommended clinical dose based on body surface area of a 20- and 60-kg patient, respectively.
Drug exposure during pregnancy lacks global fetal safety data. The maternal drug exposure birth cohort (DEBC) study, a prospective longitudinal investigation, aims to explore the correlation of maternal drug exposure during pregnancy with pregnancy outcomes, and establish a human biospecimen biobank. Here we describe the process of establishing DEBC and show that the drug exposure rate in the first trimester of pregnant women in DEBC (n = 112,986) is 30.70%. Among the drugs used, dydrogesterone and progesterone have the highest exposure rates, which are 11.97% and 10.82%, respectively. The overall incidence of adverse pregnancy outcomes is 13.49%. Dydrogesterone exposure during the first trimester is correlated with higher incidences of stillbirth, preterm birth, low birth weight, and birth defects, along with a lower incidence of miscarriage/abortion. Due to the limitations of this cohort study, causative conclusions cannot be drawn. Further follow-up and in-depth data analysis are planned for future studies.
The invention provides specific HER2 (human epidermal growth factor receptor 2) protein targeted polypeptide. The polypeptide is a mutant obtained with pertuzumab 46-65th amino acid as a template, can be specifically combined with HER2 high-expression positive breast cancer cells, and has the higher affinity than pertuzumab. The invention further provides a derivative of the polypeptide. The derivative is a bivalent or polyvalent formed from the polypeptide. The polypeptide has the character of targeting HER2 positive cancer cells, and is high in selectivity. The polypeptide can be prepared through a chemical synthesis method, is high in purity, small in molecular weight, strong in specificity, free of immunogenicity, safe and reliable, and can be used for cancer targeted therapy or cancer targeted molecular imaging and diagnosis.
PURPOSE:To provide the titled material, by dispersing beneficial enterobacterium or powder supporting beneficial enterobacterium in an oil and filling the dispersion in a specific capsule. CONSTITUTION:An oil containing dispersed beneficial enterobacterium or dispersed powder supporting said bacterium is poured out through an inner nozzle of a vibrating multiple nozzle and, at the same time, a liquid coating material is poured out through the outermost nozzle of the vibrating nozzle to form a multi-layered droplet having a diameter of <=3mm. The coating material constituting the outermost layer of the multi-layered droplet is hardened to obtain a material containing beneficial enterobacterium. The product may be further coated with an enteric coating layer. The material produced by this process has excellent storage stability and high implanting ratio. It can be easily taken to enable easy administration of a desired amount of the beneficial enterobacterium. The product is extremely suitable as a drug or food. The capsule is preferably a seamless capsule and the coating material is e.g. gelatin, alginic acid, etc.
The spatiotemporal regulation of inflammasome activation remains unclear. To examine the mechanism underlying the assembly and regulation of the inflammasome response, here we perform an immunoprecipitation-mass spectrometry analysis of apoptosis-associated speck-like protein containing a CARD (ASC) and identify NCF4/1/2 as ASC-binding proteins. Reduced NCF4 expression is associated with colorectal cancer development and decreased five-year survival rate in patients with colorectal cancer. NCF4 cooperates with NCF1 and NCF2 to promote NLRP3 and AIM2 inflammasome activation. Mechanistically, NCF4 phosphorylation and puncta distribution switches from the NADPH complex to the perinuclear region, mediating ASC oligomerization, speck formation and inflammasome activation. NCF4 functions as a sensor of ROS levels, to establish a balance between ROS production and inflammasome activation. NCF4 deficiency causes severe colorectal cancer in mice, increases transit-amplifying and precancerous cells, reduces the frequency and activation of CD8+ T and NK cells, and impairs the inflammasome-IL-18-IFN-γ axis during the early phase of colorectal tumorigenesis. Our study implicates NCF4 in determining the spatial positioning of inflammasome assembly and contributing to inflammasome-mediated anti-tumor responses.
PURPOSE: 166 Ho-diethylenetriamine pentaacetic acid(DTPA) as a liquid radiation source useful for treatment using radiation and a method for preparation of DTPA are provided. The DTPA can be used as a liquid radiation source for the treatment and prevention of restenosis in angiostenosis disease containing coronary artery. CONSTITUTION: 166 Ho-diethylenetriamine pentaacetic acid is characterized in that it is used as a liquid radiation source of a balloon catheter(1) for the prevention of restenosis in angiostenosis disease. The radiation contains βrays and γrays. The 166 Ho-DTPA is prepared by the reaction of Ho(NO3)3, HoCl3 or hydrate thereof with DTPA(diethylenetriaminepenta-acetic acid, calcium trisodium salt hydrate, Aldrich co.). The mole ratio of Ho(166H0+165Ho) and DTPA is 1:1 to 1:8.
Low Vitamin D3 (VD3) levels have been reported to be associated with the risk of allergic diseases like asthma. In addition, VD3 has been demonstrated in vitro, ex vivo (skin-explants) and in animal models to program the immune system towards anti-inflammatory immune responses, dominated by regulatory T-cells (Treg) producing Interleukin (IL)-10. In response to allergens, healthy individuals by default have such a protective immune response against innocuous allergens, whereas allergic subjects develop an inflammatory Th2-type response. VD3 co-administered with allergen may be a promising adjuvant to improve the onset and efficacy of allergen immunotherapy (AIT), by helping the allergic immune system to divert towards an allergen-specific response dominated by regulatory T cells (Treg) and IL-10. A clinical trial will be performed to compare the immune effects, the tolerability and safety of multiple doses of a VD3 analogue (Zemplar® 5 μg/ml - Abbvie, registered for the intravenous route) administered by the subcutaneous (s.c.) route in subjects with allergic rhinitis and healthy controls. Primary and secondary outcomes will be compared at baseline and at several time points during the study to investigate whether 1) the healthy controls at baseline have a more anti-inflammatory systemic cellular immune response to polyclonal stimuli and to allergens compared to birch pollen allergic subjects, and 2) whether s.c.VD3 analogue can skew these responses in allergic subjects towards a profile more resembling the one observed in healthy controls. The overall aim is to provide additional (in vivo) support for the use of VD3 as an adjuvant in allergen-specific immunotherapy, on top of the existing pre-clinical evidence demonstrating that antigen-presenting cells educate the adaptive immune system towards an anti-inflammatory response when allergen is seen in the presence of VD3.
Severe coronary calcification is still a challenge for percutaneous coronary intervention (PCI). Reduction of the calcified plaque mass is necessary to achieve adequate stent expansion during further course. Rotablation has been the only reliable option to treat extremely calcified coronary lesions for a long time. Coronary lithoplasty has been recently introduced as a new promising treatment option in this special subset. It provides the unique opportunity to break severely calcified plaque structures even inside deeper layers of the vessel wall. Aim of this study is to compare rotablation and coronary lithotripsy for treatment of severely calcified coronary lesions. Plaque structure, plaque volume, as well as lumen diameters will be analyzed by optical coherence tomography (OCT) before and after debulking, as well as after stent implantation.
Alterations utilizing nanoparticles. Certain embodiments of the invention are methods of delivering a substance to a target using a delivery-aid which includes nanoparticles. Those nanoparticles may be nanocarbon particles. Other embodiments are methods of delivering nanoparticles to a target involving placing a mask between a source of ballistic delivery of nanoparticles and the target. Other embodiments include irradiating a target to cause localized heating of the region of the target in which the nanodiamonds or OLC particles are present. Other embodiments utilize nanoparticles to make cells competent for genetic transformation. This abstract is not to be considered limiting, since other embodiments may deviate from the features described in this abstract.
Coding free text documents, especially in medicine, has become an urgent priority as electronic medical records (EMR) mature, and the need to exchange data between EMRs becomes more acute. However, only a few automated coding systems exist, and they can only code a small portion of the free text against a limited number of codes. The precision of these systems is low and code quality is not measured. The present invention discloses a process and system which implements semantic coding against standard lexicon(s) with high precision. The standard lexicon can come from a number of different sources, but is usually developed by a standard's body. The system is semi-automated to enable medical coders or others to process free text documents at a rapid rate and with high precision. The system performs the steps of segmenting a document, flagging the need for corrections, validating the document against a data type definition, and looking up both the semantics and standard codes which correspond to the document's sentences. The coder has the option to intervene at any step in the process to fix mistakes made by the system. A knowledge base, consisting of propositions, represents the semantic knowledge in the domain. When sentences with unknown semantics are discovered they can be easily added to the knowledge base. The propositions in the knowledge base are associated with codes in the standard lexicon. The quality of each match is rated by a professional who understands the knowledge domain. The system uses this information to perform high precision coding and measure the quality of the match.
Participants allocated to the treatment arm will receive intravenous 5% Human Albumin Solution (HAS) administered as the sole intravenous fluid during the initial 6-hour resuscitation period. The clinician can deliver up to 10ml/kg in the first 3 hours using 250ml boluses of HAS based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). After 3 hours further HAS boluses up to 6 hours post-randomisation will be at clinical discretion and will be documented in the CRF. Patients in the albumin arm should not receive balanced crystalloid as a resuscitation fluid in the first 6 hours.
Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
Tissue-type Plasminogen Activator (tPA) is a protein in the blood which breaks down clots and plays an important role in preventing myocardial infarction. It is produced by the endothelial cell lining of the blood vessels. Previous studies demonstrate that t-PA is released in response to the hormones bradykinin and acetylcholine. Impaired t-PA release upon bradykinin stimulation may indicate endothelial dysfunction that leads to the development of acute coronary syndrome. In this project, we will determine whether impaired t-PA release can predict future occurrence of acute coronary syndrome. The study will involve individuals getting routine left heart cardiac catheterizations (indication for cardiac catheterization is solely based on clinical indication). Prior to the procedure, patient will have two blood samples (5 ml each) collected from their forearm before and after 2 minutes blood pressure cuff inflation on their arm. After routine diagnostic cardiac catheterization and there is no severe coronary artery stenosis (\<70% stenosis), research protocol will be initiated. Study includes infusion with increasing doses of bradykinin into their left main coronary artery, and sample small amounts of blood from their coronary sinus (15 ml total).
PURPOSE:To provide a melanine-suppressing agent containing a specific p-hydroxycinnamamide derivative, having remarkable melanine-suppressing activity, free from irritancy and allergic activity to the skin, and effective to cure or mitigate the pigmentation such as spots. CONSTITUTION:The objective melanine-suppressing agent contains the p-hydroxycinnamamide derivative of formula (R is H, 1-24C alkyl, cycloaklyl, etc.). The compound of formula has remarkable melanine-suppressing effect, and is free from irritancy and allergic activity to the skin. The amount of the compound in the composition is preferably 1-20%, and is applied in the form of cream, lotion, ointment, etc. The pigmentation such as spots, freckles, suntan, etc. can be cured or improved to the sking having normal color by applying the agent to the diseased part.
The investigators propose a mini-invasive alternative technique to perform biopsies in the terminal part of the colon with rectosigmoidoscopy alone. Confocal laser endomicroscopy, either using an endoscope-based or a probe based technology , aims to decrease the number of standard biopsies and their associated risks, by providing real-time in situ microscopy. In a previous pilot study performed in 15 patients at the University hospital of Nantes, the investigators suggested that combining probe-based confocal laser endomicroscopy (pCLE) and wireless capsule endoscopy (WCE) could detect early mucosal abnormalities suggestive of GVHD and thus be part of a mini-invasive algorithm for early detection of GI-GVHD. However, in this study, the investigators showed that pCLE was a sensitive method for the early diagnosis of GVH with a sensibility of 85% and a specificity of 71.5%. These interesting results are however to put in question due to several reasons. First of all the pCLE criteria used to define a GVHD in this study were established with data stemming of literature in other validated indications such as the MIAMI score for the diagnosis of malignant biliary structures and therefore can turn out not to be as relevant as expected. Secondly the interpretations of the images obtained with pCLE were only interpreted by a single endoscopist who by the way wasn't blinded from the macroscopic appearance of eventual lesions during rectosigmoidoscopy resulting in a bias. Thirdly the number of patient as in a pilot study was probably not sufficient to evaluate the real sensibility and sensitivity of those new indication and technique for the early diagnosis of GVH. All together these observations lead us to the necessity of developing the promising results obtained previously and allow their realization by the creation of an innovating pCLE score : the E-mage score. The different criteria of the score will be established after the one defined in the pilot study reviewed by an expert committee combining anatomo-pathologists and endoscopists to be as objective as possible with quantitative and semi-quantitative assessments focusing particularly on crypt architecture, morphologic and dynamic criteria and fluorescein leakage with a cut off standing as no GVHD, likely GVHD or certain GVHD.
FIELD: medicine. ^ SUBSTANCE: glass materials are formed as a powder suspended in a nonaqueous liquid for injection to a patient. There is a problem of keeping the particles in suspension as they tend to fall on a tank bottom. Said problem is solved by adding a cellulating agent in a solution which is used to form glass. The cellulating agent is decomposed as the solution evaporates to form thereby cavities in a produced glass structure which decrease its density so that this density relates to density of the liquid in which this structure there shall be suspended. The other applications of the invention cover the compositions for inhalation and for fast dissolution in aqueous solutions immediately before use. ^ EFFECT: biological material stabilisation. ^ 24 cl, 3 dwg
1455552 Pharmaceutical composition for topical administration WARNER-LAMBERT CO 21 March 1975 [11 April 1974] 9555/75 Heading A5B A pharmaceutical composition in the form of a clear gel for topical administration having anti-inflammatory and anti-bacterial activity is prepared by dissolving a topically-active steroid (e.g. betamethasone 17-benzoate or fluocinolone acetonide) in a polyglycol (e.g. glycerol, polyethylene glycol, polypropylene glycol or butylene glycol) and adding hydroxypropyl cellulose or hydroxypropyl-methyl cellulose thereto, followed by the addition of an aqueous solution of a neomycin salt and the addition of sufficient alkali metal chloride (e.g. sodium chloride) to give a stable clear gel; except that, when neomycin hydrochloride is used, the addition of an alkali metal chloride is omitted. The polyglycol may be used in admixture with an alcoholic solvent, e.g. ethanol or isopropanol. The neomycin salt used is preferably the sulphate. The composition may also contain a thickening agent e.g. a polyethylene glycol; an anti-oxidant e.g. sodium bisulphite; and/or a chelating agent. The pH of the final composition may be adjusted to 4 to 5 with an acid, e.g. hydrochloric acid.
Hip fractures remain a substantial health concern, particularly among elderly individuals with osteoporosis, leading to high global mortality rates. This study aimed to analyze the association between body mass index (BMI) and postoperative mortality in patients who underwent surgery for hip fractures. A total of 680 patients treated at a single institution between January 2018 and December 2022 were included. Factors such as age, BMI, sex, Charlson Comorbidity Index (CCI), preoperative hemoglobin levels, American Society of Anesthesiologists score, anesthesia method, duration of surgery, and time from injury to surgery were assessed. Underweight status, male sex, higher CCI, and general anesthesia were significantly associated with 1-year and in-hospital mortality. Notably, underweight individuals exhibited a higher risk of mortality than normal-weight individuals, and female patients had lower mortality rates. This study underscores the importance of considering BMI, along with other demographic and clinical factors, in predicting postoperative mortality among patients with hip fractures, aiding the development of tailored management strategies to improve outcomes and reduce complications in this vulnerable patient population.
This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
The invention discloses a preparation method and application of a lead-free perovskite polymer scintillator, and belongs to the technical field of scintillator composite material preparation. The invention adopts high molecular polymer to grow the lead-free perovskite scintillator in situ, wherein the lead-free perovskite A is Cs 3 Cu 2 I 5 ，CsCu 2 I 3 Or (2) to (d). And adding the CsI and the CuI into a proper amount of organic solvent B, and stirring and dissolving to prepare a precursor solution A. The polymer C is at least one of polyvinylidene fluoride and polymethyl methacrylate, and C is dissolved in B. Fully mixing the solution A with the solution C to obtain a precursor colloidal solution; uniformly coating the solution on a glass substrate; then placing the glass substrate in 30-60Heating in a heater at the temperature of 60-90 minutes, and performing heat treatment after B is completely evaporated to obtain the scintillator film. The scintillator prepared by the invention has the characteristics of simple preparation process, low cost, high transparency, high flexibility, high stability, high resolution and the like, and can be used in the fields of X-ray imaging, detection and the like.